Eyevensys Appoints Dr Ivan Cohen-Tanugi as CEO

Dr Ivan Cohen-Tanugi, with over 20 years’ experience in the international pharmaceutical industry, will prepare Eyevensys to launch clinical trials for the company’s non-viral gene therapy processes in two ophthalmic indications.

For access to this article, enter your email address to instantly recieve a Password Reset link.